NASDAQ:NAUT Nautilus Biotechnology - NAUT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.41 -0.07 (-2.82%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.36▼$2.5350-Day Range$1.79▼$2.6452-Week Range$1.50▼$5.07Volume76,594 shsAverage Volume134,187 shsMarket Capitalization$300.94 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Nautilus Biotechnology MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside66.0% Upside$4.00 Price TargetShort InterestHealthy1.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.71) to ($0.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsMedical Sector573rd out of 986 stocksAnalytical Instruments Industry18th out of 28 stocks 3.0 Analyst's Opinion Consensus RatingNautilus Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Nautilus Biotechnology has a forecasted upside of 66.0% from its current price of $2.41.Amount of Analyst CoverageNautilus Biotechnology has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.80% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Nautilus Biotechnology has recently decreased by 40.39%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNautilus Biotechnology does not currently pay a dividend.Dividend GrowthNautilus Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NAUT. Previous Next 1.1 News and Social Media Coverage Search Interest4 people have searched for NAUT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Nautilus Biotechnology to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nautilus Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders41.30% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.25% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.71) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nautilus Biotechnology is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nautilus Biotechnology is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNautilus Biotechnology has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nautilus Biotechnology (NASDAQ:NAUT) StockNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.Read More Receive NAUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address NAUT Stock News HeadlinesMarch 7, 2023 | finance.yahoo.comNautilus Biotechnology Announces “First Access Challenge” WinnersFebruary 23, 2023 | finanznachrichten.deNautilus Biotechnology Inc.: Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial ResultsMarch 24, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.February 23, 2023 | msn.comNautilus Biotechnology GAAP EPS of -$0.11 beats by $0.03January 26, 2023 | finance.yahoo.comNautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023January 24, 2023 | seekingalpha.comNAUT Nautilus Biotechnology, Inc.November 1, 2022 | msn.comRecap: Nautilus Biotechnology Q3 EarningsNovember 1, 2022 | finance.yahoo.comNautilus Biotechnology Reports Third Quarter 2022 Financial ResultsMarch 24, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. October 5, 2022 | finance.yahoo.comNautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022September 23, 2022 | finance.yahoo.comNautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics SummitAugust 11, 2022 | finance.yahoo.comSujal Patel Is The Co-Founder of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) And Just Spent US$146k On SharesAugust 8, 2022 | msn.comTech Moves: Rover appoints CFO; Smartsheet adds board member; Nautilus Biotechnology hires execsAugust 4, 2022 | bizjournals.comThursday Digest: Salesforce ditches Hong Kong office; Peninsula biotech bought for $3.7BAugust 3, 2022 | seekingalpha.comNautilus Biotechnology Q2 2022 Earnings PreviewJuly 12, 2022 | finance.yahoo.comOrion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR TargetMay 3, 2022 | seekingalpha.comNautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q1 2022 Results - Earnings Call TranscriptMay 3, 2022 | finance.yahoo.comNautilus Biotechnology Reports First Quarter 2022 Financial ResultsMay 2, 2022 | seekingalpha.comNautilus Biotechnology Q1 2022 Earnings PreviewApril 12, 2022 | finance.yahoo.comNautilus Biotechnology Appoints Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent DevelopmentApril 4, 2022 | finance.yahoo.comNautilus Biotechnology to Present at EuPA and AACR MeetingsMarch 31, 2022 | finance.yahoo.comNautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of DirectorsMarch 5, 2022 | finance.yahoo.comWhat Percentage Of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Do Insiders Own?February 25, 2022 | seekingalpha.comNautilus Biotechnology GAAP EPS of -$0.13 in-lineFebruary 23, 2022 | seekingalpha.comNautilus Biotechnology Q4 2021 Earnings PreviewFebruary 22, 2022 | msn.com‘Intersection of innovation’: Why top tech VC firms are betting big on life science startupsFebruary 16, 2022 | finance.yahoo.comNautilus to Participate in the 42nd Annual Cowen Health Care ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NAUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address NAUT Company Calendar Last Earnings2/23/2023Today3/23/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NAUT CUSIPN/A CIK1808805 Webwww.nautilus.bio Phone206-333-2001FaxN/AEmployees113Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+66.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-17.45% Return on Assets-15.81% Debt Debt-to-Equity RatioN/A Current Ratio27.57 Quick Ratio27.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.53 per share Price / Book0.95Miscellaneous Outstanding Shares124,870,000Free Float73,296,000Market Cap$300.94 million OptionableOptionable Beta0.78 Key ExecutivesMr. Sujal M. Patel (Age 48)Co-Founder, CEO, Pres, Sec. & Director Comp: $652kDr. Parag Mallick Ph.D. (Age 46)Co-Founder, Chief Scientist & Director Comp: $497.55kMr. Matthew B. Murphy ESQ. (Age 58)Gen. Counsel Comp: $382.64kMs. Anna MowryCFO & TreasurerMs. Mary E. Godwin (Age 64)Sr. VP of Operations Mr. Chris BlessingtonVP of Corp. Marketing & CommunicationsMs. Gwen E. Weld (Age 65)Chief People Officer Mr. Nick A. Nelson (Age 40)Chief Bus. Officer & Sr. VP of Bus. Devel. Dr. Subra Sankar Ph.D. (Age 64)Sr. VP of Product Devel. More ExecutivesKey CompetitorsCue HealthNASDAQ:HLTHAkoya BiosciencesNASDAQ:AKYABionano GenomicsNASDAQ:BNGOSeerNASDAQ:SEERQuanterixNASDAQ:QTRXView All CompetitorsInsiders & InstitutionsMorgan StanleyBought 75,359 shares on 2/15/2023Ownership: 0.298%Skye Global Management LPSold 171,300 shares on 2/15/2023Ownership: 0.045%CI Private Wealth LLCBought 45,350 shares on 2/15/2023Ownership: 0.036%Mariner LLCBought 17,977 shares on 2/15/2023Ownership: 0.014%Shay Capital LLCBought 16,896 shares on 2/15/2023Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions NAUT Stock - Frequently Asked Questions Should I buy or sell Nautilus Biotechnology stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares. View NAUT analyst ratings or view top-rated stocks. What is Nautilus Biotechnology's stock price forecast for 2023? 2 brokers have issued 12-month price objectives for Nautilus Biotechnology's stock. Their NAUT share price forecasts range from $2.00 to $6.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 66.0% from the stock's current price. View analysts price targets for NAUT or view top-rated stocks among Wall Street analysts. How have NAUT shares performed in 2023? Nautilus Biotechnology's stock was trading at $1.80 at the start of the year. Since then, NAUT shares have increased by 33.9% and is now trading at $2.41. View the best growth stocks for 2023 here. Are investors shorting Nautilus Biotechnology? Nautilus Biotechnology saw a decline in short interest in February. As of February 28th, there was short interest totaling 894,200 shares, a decline of 40.4% from the February 13th total of 1,500,000 shares. Based on an average trading volume of 138,400 shares, the short-interest ratio is presently 6.5 days. Approximately 1.8% of the shares of the company are short sold. View Nautilus Biotechnology's Short Interest. When is Nautilus Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our NAUT earnings forecast. How were Nautilus Biotechnology's earnings last quarter? Nautilus Biotechnology, Inc. (NASDAQ:NAUT) issued its earnings results on Thursday, February, 23rd. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. What is Nautilus Biotechnology's stock symbol? Nautilus Biotechnology trades on the NASDAQ under the ticker symbol "NAUT." Who are Nautilus Biotechnology's major shareholders? Nautilus Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.77%), Clarius Group LLC (0.47%), Morgan Stanley (0.30%), Nantahala Capital Management LLC (0.23%), Sentinel Trust Co. LBA (0.15%) and Renaissance Technologies LLC (0.08%). Insiders that own company stock include Anna Mowry, Gwen E Weld, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, Subramanian Sankar and Sujal M Patel. View institutional ownership trends. How do I buy shares of Nautilus Biotechnology? Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nautilus Biotechnology's stock price today? One share of NAUT stock can currently be purchased for approximately $2.41. How much money does Nautilus Biotechnology make? Nautilus Biotechnology (NASDAQ:NAUT) has a market capitalization of $300.94 million. The company earns $-57,920,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. How many employees does Nautilus Biotechnology have? The company employs 113 workers across the globe. How can I contact Nautilus Biotechnology? Nautilus Biotechnology's mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.nautilus.bio. The company can be reached via phone at 206-333-2001 or via email at investorrelations@nautilus.bio. This page (NASDAQ:NAUT) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.